Holen Sie sich die Stockscreener-App
59.15
3.77%
2.15
Handel nachbörslich:
59.15
Schlusskurs vom Vortag:
$57.00
Offen:
$57.51
24-Stunden-Volumen:
545.00K
Relative Volume:
0.57
Marktkapitalisierung:
$2.93B
Einnahmen:
$1.36B
Nettoeinkommen (Verlust:
$123.81M
KGV:
24.54
EPS:
2.41
Netto-Cashflow:
$20.35M
1W Leistung:
+1.46%
1M Leistung:
-7.58%
6M Leistung:
-20.57%
1J Leistung:
-29.26%
1-Tages-Spanne:
$57.10
$59.31
1-Wochen-Bereich:
$55.45
$59.31
52-Wochen-Spanne:
$55.30
$97.97
Haemonetics Corp Stock (HAE) Company Profile
Firmenname
Haemonetics Corp
Sektor
Branche
Telefon
(781) 848-7100
Adresse
125 SUMMER STREET, BOSTON, MA
Vergleichen Sie HAE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
59.15 | 2.93B | 1.36B | 123.81M | 20.35M | 2.41 |
|
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-07 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-08 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-09-13 | Eingeleitet | CL King | Buy |
| 2024-09-11 | Eingeleitet | BofA Securities | Neutral |
| 2024-09-10 | Eingeleitet | BTIG Research | Buy |
| 2024-06-12 | Hochstufung | Needham | Hold → Buy |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-01-27 | Herabstufung | Needham | Buy → Hold |
| 2021-12-15 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-08-17 | Fortgesetzt | Raymond James | Outperform |
| 2021-06-17 | Eingeleitet | Citigroup | Buy |
| 2021-05-14 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2021-04-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2021-02-03 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2021-01-21 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-11-05 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-03-31 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2020-01-10 | Eingeleitet | Needham | Buy |
| 2019-08-07 | Bestätigt | Barrington Research | Outperform |
| 2019-05-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-05-08 | Bestätigt | Barrington Research | Outperform |
| 2018-08-09 | Bestätigt | Barrington Research | Outperform |
| 2018-02-07 | Bestätigt | Barrington Research | Outperform |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-11-08 | Bestätigt | Barrington Research | Outperform |
| 2017-08-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2017-07-13 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-02-07 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2016-11-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2016-11-07 | Bestätigt | The Benchmark Company | Hold |
| 2016-09-20 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2016-08-15 | Herabstufung | Sidoti | Buy → Neutral |
| 2016-08-02 | Bestätigt | Jefferies | Buy |
| 2016-08-02 | Bestätigt | The Benchmark Company | Hold |
Alle ansehen
Haemonetics Corp Aktie (HAE) Neueste Nachrichten
Reviewing Haemonetics (NYSE:HAE) and Apyx Medical (NASDAQ:APYX) - Defense World
Is Haemonetics Corporation (HAE) the Best Russell 2000 Stock to Buy According to Wall Street Analysts? - Insider Monkey
Patient Blood Management Market is Set to Experience - openPR.com
BD, Teleflex, Insulet, UFP Technologies, and Haemonetics Shares Are Falling, What You Need To Know - Yahoo Finance
Haemonetics stock touches 52-week low at $58.24 amid challenges By Investing.com - Investing.com South Africa
Haemonetics stock touches 52-week low at $58.24 amid challenges - Investing.com Australia
Q4 Earnings Highs And Lows: Haemonetics (NYSE:HAE) Vs The Rest Of The Medical Devices & SuppliesSpecialty Stocks - Yahoo Finance
Vanguard Group Inc. Purchases 10,119 Shares of Haemonetics Co. (NYSE:HAE) - Defense World
Prudential Financial Inc. Decreases Stock Holdings in Haemonetics Co. (NYSE:HAE) - Defense World
HighTower Advisors LLC Buys 244 Shares of Haemonetics Co. (NYSE:HAE) - Defense World
Haemonetics Corp. (HAE): Among the 10 Pro-Life Companies to Invest In Now? - Insider Monkey
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025 - Yahoo Finance
Haemonetics Co. (NYSE:HAE) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
10 Pro-Life Companies to Invest In Now - Insider Monkey
A Note On Haemonetics Corporation's (NYSE:HAE) ROE and Debt To Equity - Yahoo Finance
Fractional Flow Reserve Market Set for 11.27% CAGR Growth by 2031 - openPR
Haemonetics (NYSE:HAE) Given New $104.00 Price Target at Needham & Company LLC - Defense World
Is it Apt to Retain HAE Stock in Your Portfolio for Now? - Nasdaq
Demystifying Haemonetics: Insights From 5 Analyst Reviews - Nasdaq
Needham Trims Price Target on Haemonetics to $104 From $108, Keeps Buy Rating -March 18, 2025 at 06:53 am EDT - MarketScreener
Haemonetics FY2025 EPS Estimate Reduced by Zacks Research - Defense World
Raymond James Financial Inc. Takes Position in Haemonetics Co. (NYSE:HAE) - Defense World
Haemonetics Corp (HAE) Shares Down 3.63% on Mar 12 - GuruFocus.com
How Do Investors Really Feel About Haemonetics? - Benzinga
Haemonetics at Raymond James Conference: Strategic Growth Insights - Investing.com
Haemonetics at Raymond James Conference: Strategic Growth Insights By Investing.com - Investing.com UK
Haemonetics Names Chief Operating Officer, Chief Commercial Officer -March 03, 2025 at 05:40 pm EST - Marketscreener.com
Haemonetics appoints new executive leadershi - Investing.com
Haemonetics Announces Executive Leadership Updates - Quantisnow
Global Blood Bank Market to Register Immense Growth at a CAGR of ~7% by 2032 | DelveInsight - GlobeNewswire Inc.
Haemonetics Corp. to Host Earnings Call - ACCESS Newswire
Haemonetics to Present at Raymond James 46th Annual Institutional Investors Conference - Quantisnow
Zacks Research Forecasts Haemonetics’ Q3 Earnings (NYSE:HAE) - Defense World
Van ECK Associates Corp Buys Shares of 39,620 Haemonetics Co. (NYSE:HAE) - Defense World
Haemonetics FY2025 EPS Forecast Decreased by Zacks Research - Defense World
(HAE)Analyzing Haemonetics's Short Interest - Benzinga
SG Americas Securities LLC Decreases Stock Holdings in Haemonetics Co. (NYSE:HAE) - MarketBeat
Janney Montgomery Scott LLC Invests $402,000 in Haemonetics Co. (NYSE:HAE) - MarketBeat
Haemonetics (NYSE:HAE) Reaches New 12-Month Low After Analyst Downgrade - MarketBeat
Haemonetics Co. (NYSE:HAE) Given Consensus Rating of “Moderate Buy” by Brokerages - Armenian Reporter
Haemonetics Co. (NYSE:HAE) Shares Sold by Retirement Systems of Alabama - MarketBeat
Haemonetics Co. (NYSE:HAE) Shares Sold by Yousif Capital Management LLC - Defense World
Haemonetics' (NYSE:HAE) Earnings Offer More Than Meets The Eye - Yahoo Finance
Haemonetics Co. (NYSE:HAE) Receives $101.67 Average Price Target from Analysts - MarketBeat
Haemonetics (NYSE:HAE) Given New $108.00 Price Target at Needham & Company LLC - MarketBeat
Haemonetics Co. (NYSE:HAE) Receives $101.67 Consensus Target Price from Analysts - Defense World
Haemonetics (NYSE:HAE) Price Target Cut to $100.00 by Analysts at JMP Securities - MarketBeat
Haemonetics (NYSE:HAE) Raised to "Buy" at StockNews.com - MarketBeat
Haemonetics (NYSE:HAE) Downgraded to Underperform Rating by Bank of America - MarketBeat
Haemonetics' (HAE) "Strong-Buy" Rating Reaffirmed at Raymond James - MarketBeat
Haemonetics (NYSE:HAE) Reaches New 52-Week Low After Analyst Downgrade - Defense World
Finanzdaten der Haemonetics Corp-Aktie (HAE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):